Summit X LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-2,273
Closed -$24K 448
2020
Q2
$24K Buy
2,273
+523
+30% +$3.96K 0.01% 203
2020
Q1
$10K Buy
1,750
+167
+11% +$1.19K ﹤0.01% 191
2019
Q4
$10K Buy
1,583
+416
+36% +$2.87K ﹤0.01% 234
2019
Q3
$8K Hold
1,167
﹤0.01% 228
2019
Q2
$8K Hold
1,167
﹤0.01% 234
2019
Q1
$16K Hold
1,167
0.01% 238
2018
Q4
$14K Hold
1,167
0.01% 201
2018
Q3
$26K Buy
1,167
+84
+8% +$1.71K 0.01% 222
2018
Q2
$21K Buy
+1,083
New +$13.7K 0.01% 206
2018
Q1
Sell
-367
Closed -$8K 185
2017
Q4
$8K Hold
367
0.01% 178
2017
Q3
$7K Hold
367
﹤0.01% 180
2017
Q2
$13K Buy
+367
New +$15.4K 0.01% 179

Other funds holding ATNM

Summit X LLC's ATNM Position: Q3 2020 in Review

Summit X LLC sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 2,273 shares — an estimated $24K sold.

Summit X LLC first reported a position in ATNM in Q2 2017 and held it in 12 quarters. The position peaked at $26K in Q3 2018. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

  • Summit X LLC reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Summit X LLC sold 2,273 Actinium Pharmaceuticals shares in Q3 2020, an estimated $24K.
  • Summit X LLC first reported a position in Actinium Pharmaceuticals in Q2 2017 and held it in 12 quarters.
  • Summit X LLC's Actinium Pharmaceuticals position peaked at $26K in Q3 2018.
  • 41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on Summit X LLC's 13F filing for Q3 2020, filed 12 Nov 2020.